About Careers MedBlog Contact us

Pembrolizumab Approval Provides Noticeable Potential for Cancer Immunotherapy

by Madhumathi Palaniappan on September 24, 2016 at 12:48 PM
Font : A-A+

Pembrolizumab Approval Provides Noticeable Potential for Cancer Immunotherapy

The approval of Pembrolizumab drug for head and neck squamous cell carcinoma after progression of platinum based chemotherapy is an indicative advancement for treatment of the disease.

Barbara A Burtness, MD Professor of Medicine, Clinical research program leader, Head and Neck Cancers Program at Yale Cancer Center said that "Immunotherapy is a big change for head and neck cancer and there seems to be no doubt that there is activity for immunotherapies with pembrolizumab as well as nivolumab [Opdivo]"


"But one question that still remains is, 'Will there be a role for these agents in first-line therapy for patients with metastatic recurrent disease who have not previously failed a platinum-based approach?' she added.

In an interview with Onc Live, Barbara A Burtness said that there are three ongoing clinical trials for the use of immunotherapy in the first- line treatment of head and neck cancer. Two trials focused on combinations of CTLA-4 with a PD-1 drug being compared with standard cetuximab. While the other trial focused on combining chemotherapy with immunotherapy.

The trial mainly studied the use of pembrolizumab monotherapy with pembrolizumab chemotherapy using an FDA standard chemotherapy with cetuximab. And was also able to produce modest response rates for about 18% .

Regarding the independent benefits of immunotherapy and chemotherapy, pembrolizumab with chemotherapy may produce positive effects of chemotherapy along with durability of immune response.

Burtness also said that, tolerability of immunotherapies are found to be pleasing and the trial would help to prove the tolerability of integrated chemotherapy with immunotherapy. This could also be synergistic as chemotherapy could kill the cells due to DNA damage and release antigens.

To combine standard therapy with immunotherapy, burtness said that it can be either given first, during radiation or after radiation therapy. And administration of radiation therapy can produce more tumor - infiltrating lymphocytes and upregulation of PD-1 expression.

On going trial can produce upregulation of PD-1 and augmentation of TILs for immunotherapy. And may produce results on the response rate after radiation.

Source: Medindia


Recommended Reading

Latest Drug News

 India's First Urinary Incontinence Drug Launched
India's First Urinary Incontinence Drug Fesobig may offer Affordable treatment for Overactive Bladder (OAB), a widely prevalent problem among Indian men and women.
 New Ray of Hope for Atrial Fibrillation Patients With Kidney Disease
Oral anticoagulant drugs, particularly Rivaroxaban presented superior efficacy and safety than warfarin in atrial fibrillation patients with chronic kidney disease.
Anti-viral Drug Bulevirtide Helps Treat Chronic Hepatitis D
Patients with hepatitis D virus-related chronic advanced liver disease are treated with an antiviral therapy.
Antiviral Drug Paxlovid Linked to Lower Risk of Hospital Admission
Among people with COVID-19, Paxlovid drug was found to reduce hospitalization and death risk by 90%, revealed study.
Price Cap Move Will Place Eli Lilly Strongly in Insulin Market
Lilly will likely maintain or increase its market share in the insulin space as the average out-of-pocket cost for its insulin products is already below the $35 price cap.
View All
open close


Pembrolizumab Approval Provides Noticeable Potential for Cancer Immunotherapy Personalised Printable Document (PDF)

Please complete this form and we'll send you a personalised information that is requested

You may use this for your own reference or forward it to your friends.

Please use the information prudently. If you are not a medical doctor please remember to consult your healthcare provider as this information is not a substitute for professional advice.

Name *

Email Address *

Country *

Areas of Interests